Inherent Biosciences epigenetic technologies highlighted at the American Urological Association annual 2023 meeting
Salt Lake City, Utah — Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, today shared four clinical and scientific presentations from the American Urological Association (AUA) Annual 2023 Meeting in Chicago. The presentations highlight the innovative epigenetic technology in commercial development by Inherent Biosciences and the clinical utility for guiding treatment.
Here are the presentations:
Prospective Investigation of a Sperm Epigenetic Test for men seeking fertility care
Showed prospective replication of the previous SpermQT retrospective data - identifying 22% of men with a poor sperm quality who were missed by the standard of care semen analysis
Presented by Dr. Larry Lipshultz, Reproductive Urologist at Baylor College of Medicine
A Unique Epigenetic-Based Test to Accurately Predict Successful TESE and mTESE Outcomes
Blue Ribbon Best Poster Winner! AUA News is writing up a story about this and we’ll post a link here when it is published.
Presented by Dr. Larry Lipshultz, Reproductive Urologist at Baylor College of Medicine
A New Diagnostic Test: cfDNA in the Ejaculate is Predictive of Testicular Biopsy Success
The science of cell-free DNA in semen samples moving toward a liquid biopsy of the semen
Presented by Dr. Tim Jenkins, InherentBio Collaborator and Associate Professor of Cell Biology and Physiology at BYU
Long read sequencing of seminal cfDNA provides a robust prediction of the presence of sperm in the reproductive tract: implications for mTESE
1% of all men and 10-15% of men seeking fertility care are diagnosed with Non-obstructive Azoospermia (no sperm in semen) and are recommended for a testicular sperm extraction using microsurgery (mTESE)
Presented by Dr. Tim Jenkins, InherentBio Collaborator and Associate Professor of Cell Biology and Physiology at BYU
About Inherent Biosciences
Inherent Biosciences, Inc. is a biotechnology company pioneering epigenetic medicine for complex diseases. Gene dysregulation, a hallmark of complex disease, has been difficult to detect and treat, until now. The company’s epigenetic platform detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics that leverage epigenetics, biology’s inherent mechanism for gene regulation, to radically transform how we diagnose and treat complex diseases like infertility.
Connect with us on LinkedIn.
